[Effects of Bone Marrow Mesenchymal Stem Cells Derived from Patients with Newly Diagnosed Acute Myeloid Leukemia on the Cell Proliferation, Cell Cycle and Immunophenotypes of HL-60 Cells].

题目: 初诊急性髓系白血病患者来源的骨髓间充质干细胞调节HL-60细胞的增殖、细胞周期和免疫表型. 目的: 探讨急性髓系白血病(AML)患者的骨髓微环境在发病过程中的作用及AML患者间充质干细胞（MSC）对HL-60细胞的增殖、细胞周期和免疫表型的影响. RESULTS: The results of 3H-TdR incorporation assay showed that both AML-MSCs and normal MSCs remarkably suppressed the HL-60 cell proliferation in a time- and dose-dependent manner. The results of cell cycle analysis demonstrated that AML MSCs and normal MSCs induced arrest of the HL-60 cells in G0/G1 phase. The results of immunophenotyping revealed that MSCs suppressed the expression of CD11a and CD154 on the surface of HL-60 cells. Moreover, AML MSCs exhibited increased inhibitory effects than that of normal MSCs. However, no remarkable effect of MSCs on CD54 expressions of HL-60 cells was observed in the current study. 结果: 3H-TdR掺入法的结果表明，初诊AML患者骨髓MSC显著抑制HL-60增殖，并且具有良好的量效关系(r=0.998)。 细胞周期分析结果显示，MSC使HL-60细胞更多的阻滞在G0/G1期。免疫表型分析结果表明，与单独培养的HL-60细胞相比，与正常MSC和患者MSC共培养的HL-60细胞CD11a的阳性率均显著下降，分别为(50.80±10.41)% vs (36.23±8.82)%（P<0.05）和(50.80±10.41 )% vs (16.93±9.25)%（P<0.001），患者MSC共培养组和正常MSC共培养组之间也存在显著差异（16.93±9.25)% vs (36.23±8.82)%(P<0.001）。同样，与正常MSC和患者MSC共培养的HL-60细胞CD154表达也显著降低，分别为(65.67±11.91)% vs (39.85±12.11)%（P<0.01）和(65.67±11.91)% vs (17.18±9.29)%（P<0.001），且与患者MSC共培养组CD154表达降低更明显（39.85±12.11)% vs (17.18±9.29)%(P<0.05）。CD54的表达未见改变. 结论: 初诊的AML患者骨髓中存在的MSC具有与健康人骨髓MSC相似的调节HL-60增殖、细胞周期和免疫表型的能力，其抑制CD11a和CD154的能力更强于健康人骨髓MSC.